Add like
Add dislike
Add to saved papers

MiR-340-5p alleviates oxygen-glucose deprivation/reoxygenation-induced neuronal injury via PI3K/Akt activation by targeting PDCD4.

MicroRNA-340-5p (miR-340-5p), a suppressor of certain target genes in brain, reportedly is decreased in peripheral circulation of acute stroke patients. However, little is known regarding its role in regulating cerebral ischemia/reperfusion injury. This study explores the effect of miR-340-5p on ischemia/reperfusion insults by exposing rat hippocampal neurons to oxygen-glucose deprivation/reoxygenation (OGDR) in vitro. We found miR-340-5p to be poorly expressed in these neurons after OGDR stimulation. OGDR stimulation decreased cell viability, increased lactate dehydrogenase (LDH) activity and cell apoptosis, all of which were significantly inhibited by miR-340-5p overexpression and enhanced by miR-340-5p inhibition. Using bioinformatics analysis, we identified mRNA encoding the pro-apoptotic factor, programmed cell death 4 (PDCD4) as a putative target of miR-340-5p. A dual-luciferase reporter assay suggested that miR-340-5p targeted the 3'-UTR of PDCD4. PDCD4 was upregulated in cells exposed to OGDR, and miR-340-5p negatively modulated expression of PDCD4. PDCD4 overexpression partly reversed the neuroprotective effect of miR-340-5p during OGDR-induced injury. MiR-340-5p overexpression significantly promoted the activation of PI3K/Akt signaling pathway (P < 0.05) in OGDR-exposed cells, and PDCD4 overexpression attenuated this effect (P < 0.05). Collectively, our results indicate that miR-340-5p might exerted neuroprotective effects during OGDR injury by targeting PDCD4 and then activating the PI3K/Akt pathway. These results indicated a novel target for treating cerebral ischemic injury.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app